MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 177.8% in July

MetaVia Inc. (NASDAQ:MTVA) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 344,566 shares, a growth of 177.8% from the June 30th total of 124,038 shares. Approximately 6.7% of the shares of the company are sold short. Based on an average trading volume of 1,041,508 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MTVA. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. HC Wainwright reaffirmed a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Wall Street Zen raised shares of MetaVia to a “sell” rating in a research report on Saturday, June 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Stock Performance

Shares of NASDAQ:MTVA opened at $1.43 on Wednesday. The stock has a market capitalization of $7.38 million, a price-to-earnings ratio of -0.28 and a beta of 0.97. The stock’s 50-day simple moving average is $2.00 and its two-hundred day simple moving average is $1.99. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). As a group, equities analysts forecast that MetaVia will post -2.78 earnings per share for the current fiscal year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.